Skip to main content

Table 1 Characteristics for stroke patients with and without AKD

From: Association of acute kidney disease with the prognosis of ischemic stroke in the Third China National Stroke Registry

 

Total

sCr based AKD

eGFRsCr based AKD

eGFRsCysC based AKD

eGFRsCr+sCysC based AKD

Non-AKD

AKD

P

Non-AKD

AKD

P

Non-AKD

AKD

P

Non-AKD

AKD

P

n (%)

5065(100.0)

4867(96.1)

198(3.9)

––

4728(93.3)

337(6.7)

––

4565(90.1)

500(9.9)

––

4751(93.8)

314(6.2)

––

Age (year), n (%)

   

0.83

  

0.008

  

0.01

  

0.34

 < 60

2032(40.1)

1954(40.1)

78(39.4)

 

1920(40.6)

112(33.2)

 

1857(40.7)

175(35.0)

 

1914(40.3)

118(37.6)

 

 ≥ 60

3033(59.9)

2913(59.9)

120(60.6)

 

2808(59.4)

225(66.8)

 

2708(59.3)

325(65.0)

 

2837(59.7)

196(62.4)

0.34

Male gender, n (%)

3453(68.2)

3327(68.4)

126(63.6)

0.16

3237(68.5)

216(64.1)

0.10

3107(68.1)

346(69.2)

0.60

3255(68.5)

198(63.1)

0.04

TIA, n (%)

412(8.1)

395(8.1)

17(8.6)

0.81

381(8.1)

31(9.2)

0.46

364(8.0)

48(9.6)

0.21

382(8.0)

30(9.6)

0.34

TOAST, n (%)

   

0.13

  

0.17

  

0.004

  

0.10

SAO

1213(24.0)

11,178(24.2)

35(17.7)

 

1149(24.3)

64(19.0)

 

1118(24.5)

95(19.0)

 

1155(24.3)

58(18.5)

 

LAA

1252(24.7)

1193(24.5)

59(29.8)

 

1163(24.6)

89(26.4)

 

1109(24.3)

143(28.6)

 

1165(24.5)

87(27.7)

 

CE

265(5.2)

255(5.2)

10(5.1)

 

245(5.2)

20(5.9)

 

229(5.0)

36(7.2)

 

245(5.2)

20(6.4)

 

Other or undetermined

2335(46.1)

2241(46.0)

94(47.5)

 

2171(45.9)

164(48.7)

 

2109(46.2)

226(45.2)

 

2186(46.0)

149(47.5)

 

Medical history

Hypertension

3177(62.7)

3045(62.6)

132(66.7)

0.24

2945(62.3)

232(68.8)

0.02

2816(61.7)

361(72.2)

 < 0.001

2955(62.2)

222(70.7)

0.003

Diabetes

1158(22.9)

1097(22.5)

61(30.8)

0.007

1057(22.5)

101(30.0)

0.001

1019(22.3)

139(27.8)

0.006

1067(22.5)

91(29.0)

0.008

Dyslipidemia

437(8.6)

422(8.7)

15(7.6)

0.59

402(8.5)

35(10.4)

0.23

385(8.4)

52(10.4)

0.14

398(8.4)

39(12.4)

0.01

Coronary heart disease

527(10.4)

506(10.4)

21(10.6)

0.92

481(10.2)

46(13.7)

0.04

459(10.1)

68(13.6)

0.01

482(10.2)

45(14.3)

0.02

Clinical characteristics on admission

NIHSS, n (%)

   

0.01

  

 < 0.001

  

 < 0.001

  

0.25

< 5

3441(67.9)

3325(68.3)

116(58.6)

 

3242(68.6)

199(58.1)

 

3146(68.9)

295(59.0)

 

3241(68.2)

200(63.7)

 

5–15

1548(30.6)

1471(30.2)

77(38.9)

 

1423(30.1)

125(37.1)

 

1353(29.6)

195(39.0)

 

1439(30.3)

109(34.7)

 

> 15

76(1.5)

71(1.5)

5(2.5)

 

63(1.3)

13(3.9)

 

66(1.5)

10(2.0)

 

71(1.5)

5(1.6)

 

mRS, n (%)

   

0.08

  

0.07

  

 < 0.001

  

0.04

0–2

3626(71.6)

3495(71.8)

131(66.2)

 

3399(71.9)

227(67.4)

 

3301(72.3)

325(65.0)

 

3417(71.9)

1334(28.08)

209(66.6)

 

3–5

1439(28.4)

1372(28.2)

67(33.8)

 

1329(28.1)

110(32.6)

 

1264(27.7)

175(35.0)

 

1334(28.08)

105(33.4)

 

BMI (Kg/m2), mean ± SD

24.8 ± 3.3

24.8 ± 3.3

24.4 ± 3.4

0.11

24.8 ± 3.3

24.6 ± 3.8

0.44

24.8 ± 3.3

24.5 ± 3.4

0.10

24.8 ± 3.3

24.5 ± 3.9

0.19

sCr (umol/L), median (IQR)

69.0(58.0–80.0)

69.0(59.0–80.0)

54.5(29.0–103.0)

 < 0.001

68.0(58.0–79.0)

101.0(69.0–125.0)

 < 0.001

69.0(58.0–80.0)

71.0(60.0–84.5)

 < 0.001

69.0(58.0–80.0)

78.0(53.0–114.0)

 < 0.001

sCysC (mg/L), median (IQR)

0.94(0.83–1.07)

0.94(0.83–1.07)

0.96(0.80–1.19)

0.11

0.93(0.83–1.06)

1.05(0.90–1.30)

 < 0.001

0.93(0.83–1.06)

0.98(0.84–1.20)

 < 0.001

0.93(0.83–1.06)

1.04(0.86–1.36)

 < 0.001

eGFRsCr (mL/min/1.73m2), n (%)

   

 < 0.001

  

 < 0.001

  

 < 0.001

  

 < 0.001

 < 60

325(6.4)

272(5.6)

53(26.8)

 

168(3.6)

157(46.6)

 

266(5.8)

59(11.8)

 

220(4.6)

105(33.4)

 

60 ~ 89

1649(32.6)

1626(33.4)

23(11.6)

 

1551(32.8)

98(29.1)

 

1462(32.0)

187(37.4)

 

1574(33.1)

75(23.9)

 

 ≥ 90

3091(61.0)

2969(61.0)

122(61.6)

 

3009(63.6)

82(24.3)

 

2837(62.2)

254(50.8)

 

2957(62.2)

134(42.7)

 

eGFRsCysC (mL/min/1.73m2), n (%)

   

 < 0.001

  

 < 0.001

  

 < 0.001

  

 < 0.001

 < 60

741(14.6)

690(14.2)

51(25.8)

 

627(13.3)

114(33.8)

 

599(13.1)

142(28.4)

 

626(13.2)

115(36.6)

 

60 ~ 89

2427(47.9)

2347(48.2)

80(40.4)

 

2280(48.2)

147(43.6)

 

2224(48.7)

203(40.6)

 

2312(48.7)

115(36.6)

 

 ≥ 90

1897(37.5)

1830(37.6)

67(33.8)

 

1821(38.5)

76(22.6)

 

1742(38.2)

155(31.0)

 

1813(38.2)

84(26.8)

 

eGFRsCr+sCysC (mL/min/1.73m2), n (%)

   

 < 0.001

  

 < 0.001

  

 < 0.001

  

 < 0.001

 < 60

425(8.4)

371(7.6)

54(27.3)

 

293(6.2)

132(39.2)

 

344(7.5)

81(16.2)

 

320(6.7)

105(33.4)

 

60 ~ 89

2266(44.7)

2227(45.8)

39(19.7)

 

2136(45.2)

130(38.6)

 

2036(44.6)

230(46.0)

 

2170(45.7)

96(30.6)

 

 ≥ 90

2374(46.9)

2269(46.6)

105(53.0)

 

2299(48.6)

75(22.3)

 

2185(47.9)

189(37.8)

 

2261(47.6)

113(36.0)

 

Medication in hospitalization, n (%)

Dehydrant

186(3.7)

178(3.7)

8(4.0)

0.78

168(3.6)

18(5.3)

0.09

156(3.4)

30(6.0)

0.004

169(3.6)

17(5.4)

0.09

ACEI/ARBs

829(16.4)

794(16.3)

35(17.7)

0.61

770(16.3)

59(17.5)

0.56

725(15.9)

104(20.8)

0.005

772(16.3)

57(18.2)

0.38

  1. AKD Acute kidney disease, SD Standard deviation, IQR Interquartile range, sCr Serum creatinine, sCysC Serum cystatin C, eGFR Estimated glomerular filtration rate, TIA Transient ischemic attack, TOAST Stroke subtype defined by the Trial of Org 10,172 in Acute Stroke Treatment classification, LAA Large-artery atherosclerosis, SAO Small-artery occlusion, CE Cardioembolism; mRS, modified Rankin Scale, NIHSS National Institutes of Health stroke scale, BMI Body mass index, ACEI/ARBs Angiotensin converting enzyme inhibitors/angiotensin receptor blockers
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us